Immucor to increase volume of shares:
This article was originally published in Clinica
Executive Summary
Immucor's existing shareholders are to receive a 50% stock dividend following the company's decision to go ahead with a 3-for-2 stock split. The move will increase the number of shares of common stock outstanding from over 20 million, as recorded at the end of May, to over 30 million. The expected date of distribution is July 16. Since received FDA approval for its fully automated Galileo blood sample analyser in April, the company saw its share price go up nearly 27%. According to the Norcross, Georgia-based company, the aim in increasing the number of shares is to make the price of its stock more accessible to investors of all levels. This is the sixth stock split for Immucor since its IPO in December 1985.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.